Description: Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Home Page: arecor.com
AREC Technical Analysis
Chesterford Research Park
Little Chesterford,
CB10 1XL
United Kingdom
Phone:
44 1223 426 060
Officers
| Name | Title |
|---|---|
| Dr. Sarah Jennifer Howell Ph.D. | CEO & Director |
| Ms. Susan Day Lowther FCMA | CFO, Company Sec. & Director |
| Dr. Jan Jezek Ph.D. | Chief Scientific Officer |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.2515 |
| Price-to-Sales TTM: | 53.254 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 37 |